PMID: 11898538Mar 20, 2002Paper

Initial treatment of early Parkinson's disease: a review of recent, randomized controlled trials

Current Neurology and Neuroscience Reports
K Biglan, R G Holloway

Abstract

Many studies have shown dopamine agonists to significantly improve parkinsonian symptoms compared with placebo in early Parkinson's disease (PD), but how do agonists compare with the standard treatment of levodopa? Recently, three large, multicenter, randomized controlled studies directly comparing a dopamine agonist with levodopa as initial therapy in early PD have been published. These studies suggest that although both agents effectively ameliorate parkinsonian symptoms, levodopa was superior to dopamine agonists as measured by improvement in Unified Parkinson's Disease Rating Scale (UPDRS) scores. However, levodopa was more frequently associated with dopaminergic motor complications, and the dopamine agonists were more commonly associated with adverse events. Until further studies clearly demonstrate the beneficial effects of one therapeutic strategy over another, the decision to initiate treatment in early PD with either an agonist or levodopa will be based on the favorable motor complication profile of agonists versus the more potent antiparkinsonian effects and the favorable side-effect profile of levodopa.

References

Sep 1, 1977·Acta Neurologica Scandinavica·O Kristensen, E Hansen
Mar 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·M A HelyG A Broe
Jun 1, 1989·Journal of Neurology, Neurosurgery, and Psychiatry·J L MontastrucA Rascol
Dec 1, 1996·Neurology·S Fahn
Dec 17, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·M WelshC H Waters
Feb 6, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·O RascolF Stocchi
May 5, 1998·Neurology·Y Agid
Aug 26, 1998·Neurology·M Yamamoto
Nov 25, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·A SchragN Quinn
Feb 1, 2000·Journal of Neurology·F GrandasC Tabernero
Mar 14, 2000·Archives of Neurology·W J Weiner
May 5, 2000·The Cochrane Database of Systematic Reviews·E Clarke C, M Speller J
May 16, 2000·Journal of Neural Transmission·N GiladiA D Korczyn
Jul 25, 2000·The Cochrane Database of Systematic Reviews·E Clarke CA Clarke J
Sep 1, 2000·Journal of the American Geriatrics Society·D AarslandK Laake
Oct 18, 2000·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group

❮ Previous
Next ❯

Citations

Aug 21, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·David A FishbainJinrun Gao
Nov 8, 2014·The Cochrane Database of Systematic Reviews·Maria KleinstäuberMichael J Lambert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.